Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* ≥ 2 prior lines of therapy which must have included at least 2 consecutive cycles of lenalidomide and a proteosome inhibitor alone or in combination~* Documented refractory or relapsed and refractory multiple myeloma~* Refractory to proteosome inhibitor and lenalidomide, and to last treatment~* Relapsed and refractory patients must have achieved at least a partial response to previous treatment with proteosome inhibitor or lenalidomide, or both, but progressed within 6 months, and were refractory to their last treatment~* Measurable disease at screening~* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2~Exclusion Criteria:~* Active plasma cell leukemia~* Prior treatment with pomalidomide~* Unable to tolerate thromboembolic prophylaxis while on the study~* Prior autologous stem cell transplant within 12 weeks~* Known Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Elotuzumab Arm (Type: EXPERIMENTAL): Biological:Elotuzumab (BMS-901608; HuLuc63)~* Solution, Intravenous(IV),10 mg/kg(Cycles 1 and 2 weekly, on Days 1,8,15,22)~* Solution, Intravenous(IV),20 mg/kg(Cycle 3 and Beyond: Day 1)~Drug: Pomalidomide~•Capsules,Oral,4 mg,once daily, on Days 1-21~Other Name: Pomalyst~Drug: Dexamethasone~* Subjects ≤ 75 years old:~  •Tablets, Oral,28 mg, once daily on: Days 1,8,15,22(Cycles 1\&2) Day 1(Cycle 3 and Beyond)~  •Solution, Intravenous(IV), 8 mg, once daily on: Days 1,8,15,22(Cycles 1\&2) Day 1(Cycle 3 and Beyond)~  •Tablets, Oral,40 mg, once daily on: Days 8,15,22(Cycle 3 and Beyond)~* Subjects \> 75 years old:~  •Tablets, Oral,8 mg, once daily on: Days 1,8,15,22(Cycles 1\&2) Day 1(Cycle 3 and Beyond)~  •Solution, Intravenous(IV), 8 mg, once daily on: Days 1,8,15,22(Cycles 1\&2) Day 1(Cycle 3 and Beyond)~  •Tablets, Oral, 20 mg, once daily on: Days 8,15,22(Cycle 3 and Beyond)~Other Names:~Decadron,Dexamethasone ,Intensol,Dexpak,Taperpak
- Control Arm (Type: ACTIVE_COMPARATOR): Drug: Pomalidomide~• Capsules, Oral, 4 mg, once daily, on Days 1-21 Other Name: Pomalyst~Drug: Dexamethasone~Subjects ≤ 75 years old:~• Tablets, Oral, 40 mg, weekly on Days 1, 8, 15 and 22~Subjects \> 75 years old:~• Tablets, Oral, 20 mg, weekly on Days 1, 8, 15 and 22,~Other Names:~* Decadron~* Dexamethasone Intensol~* Dexpak~* Taperpak

Based on this trial design, predict the completion outcome and termination type (if applicable).